Azelby Robert
SEC-identified person · CIK 1656998 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Tango Therapeutics, Inc. TNGX | Director | filed 2026 - 2026 |
| ADC Therapeutics SA ADCT | Director | filed 2024 - 2026 |
| Terns Pharmaceuticals, Inc. TERN | Director | filed 2025 - 2026 |
| Autolus Therapeutics plc AUTL | Director | filed 2026 - 2026 |
| Cardinal Health INC CAH | Director | filed 2024 - 2025 |
| Chinook Therapeutics, INC. KDNY | Director | filed 2023 - 2023 |
| Eliem Therapeutics, Inc. ELYM | Director · President & CEO | filed 2021 - 2022 |
| Clovis Oncology, Inc. CLVS | Director | filed 2018 - 2021 |
| Immunomedics INC IMMU | Director | filed 2020 - 2020 |
| Alder Biopharmaceuticals INC ALDR | Director · President and CEO | filed 2018 - 2019 |
| Oncothyreon Inc. ONTY | Director | filed 2017 - 2018 |
| Juno Therapeutics, Inc. JUNO | See Remarks | filed 2015 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.